Research Analysts Offer Predictions for Ionis Pharmaceuticals Inc’s FY2019 Earnings (NASDAQ:IONS)

Share on StockTwits

Ionis Pharmaceuticals Inc (NASDAQ:IONS) – Svb Leerink raised their FY2019 earnings per share estimates for Ionis Pharmaceuticals in a research note issued on Thursday, December 5th. Svb Leerink analyst M. Foroohar now expects that the company will post earnings per share of $1.64 for the year, up from their prior estimate of $1.60. Svb Leerink also issued estimates for Ionis Pharmaceuticals’ Q3 2020 earnings at $0.16 EPS, Q4 2020 earnings at $0.29 EPS and FY2020 earnings at $0.44 EPS.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.49. Ionis Pharmaceuticals had a net margin of 52.26% and a return on equity of 36.31%. The firm had revenue of $168.00 million during the quarter, compared to analysts’ expectations of $152.47 million. During the same period in the previous year, the company earned ($0.03) EPS. The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year.

A number of other equities research analysts have also weighed in on the stock. BidaskClub upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, December 5th. Bank of America began coverage on shares of Ionis Pharmaceuticals in a report on Wednesday, November 13th. They set a “buy” rating and a $70.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and set a $87.00 price objective on shares of Ionis Pharmaceuticals in a report on Thursday, November 7th. ValuEngine upgraded shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, December 3rd. Finally, Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $65.00 price objective for the company in a report on Saturday, November 16th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $75.55.

Shares of IONS opened at $62.91 on Monday. Ionis Pharmaceuticals has a 1-year low of $48.27 and a 1-year high of $86.58. The company has a 50-day moving average of $59.09 and a 200 day moving average of $62.89. The firm has a market capitalization of $8.85 billion, a price-to-earnings ratio of 21.25, a PEG ratio of 2.32 and a beta of 1.91. The company has a debt-to-equity ratio of 0.44, a current ratio of 10.39 and a quick ratio of 10.31.

Large investors have recently bought and sold shares of the company. CWM LLC raised its holdings in shares of Ionis Pharmaceuticals by 361.4% in the 2nd quarter. CWM LLC now owns 406 shares of the company’s stock valued at $26,000 after purchasing an additional 318 shares in the last quarter. Quest Capital Management Inc. ADV bought a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $36,000. Rehmann Capital Advisory Group raised its stake in shares of Ionis Pharmaceuticals by 41.3% during the 2nd quarter. Rehmann Capital Advisory Group now owns 592 shares of the company’s stock worth $38,000 after acquiring an additional 173 shares in the last quarter. Venturi Wealth Management LLC bought a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $40,000. Finally, Bradley Foster & Sargent Inc. CT bought a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $49,000. Institutional investors and hedge funds own 85.65% of the company’s stock.

In other news, SVP Richard S. Geary sold 5,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $65.06, for a total value of $325,300.00. Following the completion of the sale, the senior vice president now owns 26,583 shares in the company, valued at approximately $1,729,489.98. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Joseph Klein III sold 2,000 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $60.00, for a total transaction of $120,000.00. Following the completion of the sale, the director now owns 13,495 shares of the company’s stock, valued at approximately $809,700. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,154 shares of company stock valued at $2,333,382. Company insiders own 2.40% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Featured Article: FAANG Stocks

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.